ALXO | tickerfilter.com

Fundamental analysis

37%

Profitability 35%

Dept financing 25%

Liquidity 50%

Performance 40%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-7.69%

1 Month

-17.74%

3 Months

34.21%

6 Months

72.88%

1 Year

109.57%

2 Year

-84.84%

Key data

Stock price

$2.04

P/E Ratio

3.65

DAY RANGE

$2.02 - $2.30

EPS

-$2.10

52 WEEK RANGE

$0.40 - $2.66

52 WEEK CHANGE

$112.63

MARKET CAP

97.999 M

YIELD

N/A

SHARES OUTSTANDING

54.218 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-08-2025

BETA

0.56

PUBLIC FLOAT

AVERAGE 10 VOLUME

$605,816

AVERAGE 30 VOLUME

$872,163

Company detail

CEO: Jaume Pons
Region: US
Website: alxoncology.com
Employees: 40
IPO year: 2020

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

ALX Oncology Holdings Inc. focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial. ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer.

ALXO - Alx Oncology Holdings Inc